###### Significance of this study

What is already known about this subject?
=========================================

-   The longitudinal association of postprandial lipemia with cardiovascular disease risk is not clear, stemming from limitations in how postprandial variables have been assessed in prospective studies.

What are the new findings?
==========================

-   There were no statistically significant associations between any of the multiple measures of postprandial change used in this study and incident cardiovascular outcomes.

How might these results change the focus of research or clinical practice?
==========================================================================

-   More powered prospective studies using detailed, standardised measures of postprandial change are needed to elucidate the association of postprandial lipemia with the development of cardiovascular disease.

Introduction {#s1}
============

Postprandial lipemia (PPL) refers to the metabolic state in which there is an increase of triglyceride-rich lipoproteins in circulation following fatty food consumption. While exaggerated levels of such triglycerides during PPL have been linked to prevalent atherosclerosis and cardiovascular disease (CVD) in case--control studies,[@R1] [@R2] understanding of the association between PPL and incident atherothrombotic events is hampered by limitations in how PPL was assessed in previous longitudinal investigations.[@R3] These studies, while extremely large in scale, used fasting or non-fasting postprandial triglycerides measured by a non-standardised protocol and at only one point in time.

Reliance on non-fasting triglycerides is flawed due to the high variability in their concentrations depending on the timing and contents of the last meal. Reported associations between fasting triglycerides and incident CVD events have been noticeably attenuated on adjustment for high-density lipoprotein cholesterol (HDL-C), ensuing debate in terms of whether excessive PPL confers any residual risk on the development of CVD beyond its relationship with HDL-C.[@R7] Furthermore, concentrations of triglycerides taken at a single time point are not necessarily accurate indicators of postprandial change.[@R9] Valid assessment of postprandial change is achieved instead through the synthesis of repeat measurements of postprandial moieties obtained over the course of a fat-tolerance test.[@R9] Given the lack of prospective investigations with such detailed, standardised measures of postprandial change, the role PPL plays in CVD development is unclear.

Our study reassessed the longitudinal relationship between PPL and CVD using standardised fat challenge measures of postprandial change in a subsample from the population-based Atherosclerosis Risk in Communities (ARIC) Study. Associations of postprandial change with incident CVD events over ∼20 years were estimated in white and African-American men and women. We further examined associations between these PPL measures and CVD risk by subgroups of race, body mass index (BMI) and baseline carotid intima media thickness (IMT), a measure of atherosclerosis severity.

Research design and methods {#s2}
===========================

Study population {#s2a}
----------------

The ARIC Study is an ongoing community-based cohort of 15 792 men and women (mostly whites and African-Americans) aged 45--64 years at baseline (1987--1989) who were probabilistically selected from four US communities (Forsyth County, North Carolina; Jackson, Mississippi; suburbs of Minneapolis, Minnesota and Washington County).[@R10] Our study sample originated from 1114 ARIC participants invited into a nested case--control study during ARIC visit 2, which occurred from 1990 to 1993.[@R1] [@R11] This substudy, composed of cases with subclinical carotid atherosclerosis and controls with minimal or no carotid artery atherosclerosis, was designed to examine the relationship between PPL and subclinical atherosclerosis, among participants without prevalent CVD.[@R1] [@R11]

Fat-tolerance test {#s2b}
------------------

After a 12-hour period of fasting and avoidance of exercise, fasting blood specimens were collected. A liquid test meal was then administered, which consisted of heavy whipping cream, ice cream, safflower oil, chocolate syrup and powdered protein (Promod, Ross Laboratories) and contained 1265 kcal, 32 g protein, 48 g carbohydrate, 105 g fat (52 g saturated) and 300 mg cholesterol, in addition to 100 000 IU vitamin A (Aquasol, Armour Pharmaceutical Co.) for each 2 m^2^ of body surface area. As a safeguard against potential lactose intolerance, Lactaid was added to the meal. Participants were allotted 15 min to consume the test meal and instructed to ingest only water, unsweetened coffee or tea or sugarless soft drinks for 8 hours thereafter. Blood specimens were drawn 3.5 and 8 hours following test meal consumption. The number of postprandial blood collections (ie, the difference between two and four measurements) has shown minimal influence on the classification of postprandial response.[@R2] Hence, measurements of PPL variables taken post-fasting and then 3.5 and 8 hours after consumption of the test meal should be suitable to assess postprandial response to a fatty meal over an 8-hour time period.

Blood specimens were centrifuged for 20 min (1500 *g*, at 4°C) to separate plasma. Plasma samples were shipped on dry ice and stored in liquid nitrogen at the central laboratory until analysis within a few days. Details of this procedure have been described elsewhere.[@R1] [@R11]

PPL assays {#s2c}
----------

Variation in CVD risk by subclasses of PPL-related variables was considered by using four separate measures of postprandial markers (each assessed at visit 2): postprandial triglycerides (TG), TG-rich lipoprotein triglycerides (TRL-TG), retinyl palmitate (RP) and apolipoprotein B48 to apolipoprotein B100 ratio (apoBR). TG and TRL-TG appear in the 'top fraction' and are markers of very low-density lipoproteins, whereas measures of RP and apoBR are surrogates for chylomicrons. In this study, TG levels were measured enzymatically, TRL-TG samples were isolated by ultracentrifugation,[@R12] plasma RP levels were determined using high-pressure liquid chromatography[@R13] and apoBR values were ascertained by sodium dodecyl sulfate electrophoresis.[@R14]

To yield a measure of postprandial change, the incremental area under the curve (iAUC) defined by each PPL parameter across the available time points (0, 3.5 and 8 hours after the test meal) was calculated, with negative results set to 0.[@R1] For the purposes of this study, the iAUC can be interpreted as the two-dimensional postprandial response over 8 hours. The iAUC measures were transformed into weighted SD units to reflect the sampling weights of the overall ARIC sample from which case--control participants were drawn. Weighted SD units can be interpreted in the same manner as conventional SD units.

Other covariates {#s2d}
----------------

HDL-C and low-density lipoprotein cholesterol (LDL-C) were measured at visit 2.[@R15] [@R16] Trained ARIC personnel used a standardised protocol to measure height, weight, former as well as current cigarette smoking status and diastolic and systolic blood pressure at visit 2.[@R17] Prevalent hypertension was indicated by a systolic blood pressure ≥140 mm Hg, a diastolic blood pressure ≥90 mm Hg and/or self-reported use of antihypertensive medication. The use of lipid-lowering medications was self-reported by the patient and verified by ARIC personnel (checking of medications brought by the patient) at visit 2. Fasting blood glucose measures were also taken at visit 2.

Severity of atherosclerosis was assessed using B-mode ultrasound as in the aforementioned nested case--control study during visit 2.[@R1] [@R11] In that study, white participants with IMT values above the 95th centile of the ARIC distribution were sampled as cases, while the 90th centile was applied to obtain a sufficient number of cases among black participants. Controls in race/ethnicity groups were below the 75th centile of IMT in all artery segments evaluated, as IMT values greater than the 75th centile are considered abnormal and indicative of increased CVD risk.[@R18] Cases from that study were classified as having a high severity of atherosclerosis in this study, and controls as having a low severity of atherosclerosis.

Ascertainment of CVD {#s2e}
--------------------

Incident CHD events included definite or probable myocardial infarction (MI), 'silent' MI per centrally interpreted ECG, definite CHD death or coronary revascularisation. This information was obtained through annual contact of participants, yearly discharge lists from local hospitals and ongoing survey of death certificates.[@R17] Incident (ischaemic) stroke was identified through hospital discharge codes and deaths attributed to stroke.[@R19] Physician reviewers adjudicated all possible CHD and stroke events and classified them as definite, probable or non-events based on information abstracted from medical records.[@R19] Cohort follow-up of incident CHD and stroke events through 31 December 2012 was included in these analyses.

Statistical analyses {#s2f}
--------------------

Plots of residuals depicted a relatively linear relationship between each PPL parameter (as the iAUC-transformed weighted SD measure) and incident CVD (CHD or stroke). For each PPL parameter, we therefore estimated crude, age-sex adjusted and fully adjusted associations between an increase of 1-unit in the iAUC-transformed weighted SD measure and incident CVD events (CHD individually, stroke individually, and CHD or stroke as a merged outcome). Cox proportional hazard models[@R20] were used to quantify estimates of associations on the relative scale via HRs, and incident rate differences (IRDs) from Poisson models[@R21] were used as estimates on the absolute scale.

Since knowledge of the biological mechanism involved in postprandial change and CVD development is not clear, we applied stepwise selection (p\<0.15 for inclusion and exclusion)---as opposed to a priori adjustment---to guide in the choice of covariates for fully adjusted models. The following variables, each at visit 2, were considered in such models: age, sex, race (white or African-American), study center location, BMI (≥30 kg/m^2^ or\<30 kg/m^2^), atherosclerosis severity (high or low), HDL-C, LDL-C, fasting blood glucose, current cigarette smoking, former cigarette smoking, prevalent hypertension and use of lipid-lowering medications.

As per findings from the ARIC case--control study of PPL and atherosclerosis,[@R1] we also estimated associations of our PPL measures with incident CVD by dichotomies of race, BMI and atherosclerosis severity. Comparison of effect measures across these subgroups of low versus high cardiometabolic risk may provide insights into the temporality and etiology of potential mechanisms. For instance, evidence of an independent association between excessive PPL and incident CVD in participants with low but not high IMT would suggest that PPL exerts its role in the pathophysiology of CVD prior to or during the earlier stages of atherosclerosis. In this study, all statistical analyses were performed using SAS V.9.3 (SAS Corp, Cary, North Carolina, USA).

Results {#s3}
=======

Of 1114 participants invited into the original ARIC case--control study, 555 individuals were excluded from this study (84 declined participation, 195 had prevalent CVD, 179 had other medical exclusions and 97 had test meal intolerance). Our final analytic sample consisted of 559 participants---228 (41%) women and 148 (26%) African-Americans distributed similarly across the four study sites. Baseline characteristics of participants are presented in [table 1](#BMJDRC2016000335TB1){ref-type="table"}.

###### 

Characteristics of study participants (N=559) from the ARIC nested case--control study of PPL and atherosclerosis during 1990--1993 by tertiles of the AUC-transformed weighted SD measure of postprandial triglycerides (TG)

                                           TG tertile                
  ---------------------------------------- ------------ ------------ ------------
  Age mean (SD), years                     57.9 (5.6)   58.6 (5.3)   58.1 (5.4)
  Sex                                                                
   Female, n (%)                           103 (56)     69 (37)      54 (29)
   Male, n (%)                             82 (44)      116 (63)     131 (71)
  Race                                                               
   African-American, n (%)                 47 (25)      48 (26)      50 (27)
   White, n (%)                            138 (75)     137 (74)     135 (73)
  Study centre                                                       
   Forsyth, NC, n (%)                      34 (18)      47 (25)      59 (32)
   Jackson, MS, n (%)                      46 (25)      46 (25)      48 (26)
   Minneapolis, MN, n (%)                  63 (34)      43 (23)      44 (24)
   Washington County, MD, n (%)            42 (23)      49 (27)      34 (18)
  BMI                                                                
   ≥30 kg/m^2^, n (%)                      29 (16)      42 (23)      42 (23)
   \<30 kg/m^2^, n (%)                     156 (84)     143 (77)     143 (77)
  Carotid IMT level                                                  
   High, n (%)                             52 (28)      70 (38)      80 (43)
   Low, n (%)                              133 (72)     115 (62)     105 (57)
  HDL-C mean (SD), mg/dL                   14.2 (8.5)   10.3 (6.4)   8.2 (4.8)
  LDL-C mean (SD), mg/dL                   124 (32)     131 (36)     139 (31)
  Fasting blood glucose mean (SD), mg/dL   108 (36)     111 (38)     108 (30)
  Current cigarette smoking                                          
   Smoker, n (%)                           40 (22)      48 (26)      50 (27)
   Non-smoker, n (%)                       145 (78)     136 (74)     135 (73)
  Former cigarette smoking                                           
   Smoker, n (%)                           67 (36)      71 (39)      81 (44)
   Non-smoker, n (%)                       118 (64)     113 (61)     104 (56)
  Prevalent hypertension                                             
   Present, n (%)                          52 (28)      48 (26)      49 (27)
   Absent, n (%)                           133 (72)     136 (74)     135 (73)

HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

The mean values of the iAUC-transformed weighted SD measures of PPL at visit 2 were 1.7 for TG, 1.4 for TRL-TG, 1.9 for RP and 1.4 for apoBR. The means of the iAUC PPL measures prior to weighted SD transformation were 708 mg/dL×hour (SD=473) for TG, 536 mg/dL×hour (SD=432) for TRL-TG, 5781 µg/L×hr (SD=3051) for RP and 15 hour (SD=12) for apoBR. Before iAUC calculations were performed, the mean values of the PPL parameters were 121 mg/dL (SD=60) for TG, 71 mg/dL (SD=54) for TRL-TG, 19 µg/L (SD=36) for RP and 3.0 (SD=1.8) for apoBR.

A total of 127 (23%) incident cases of CHD and 27 (5%) incident cases of stroke accrued in the study sample by the end of 2012 (median follow-up=20.5 years). The study was sufficiently powered (at 80%) to detect an HR=1.3 in the overall sample. However, analyses in the overall sample did not reveal any significant associations between the PPL measures and incident CHD or stroke ([table 2](#BMJDRC2016000335TB2){ref-type="table"}). Point estimates of effect sizes (HRs and IRDs) were generally null, even in crude models. As interpreted using the 95% CIs of fully adjusted HRs, estimates of the excess CVD risk (attributed to each 1-unit increase in the iAUC-transformed weighted SD of RP, in this case) are not expected to surpass 28% in 95% of study repetitions.

###### 

HR and IRD estimates (with 95% CIs and p values) for associations between an increase of 1-unit in the iAUC-transformed weighted SD measure of each PPL parameter and incident CHD or stroke

  PPL parameter     Model   N     Events                HR (95% CI)           p Value               IRD\* (95% CI)        p Value
  ----------------- ------- ----- --------------------- --------------------- --------------------- --------------------- ---------
  TG                Crude   534   123                   0.94 (0.80 to 1.11)   0.459                 −4.1 (−12.4 to 5.0)   0.382
  Age and sex       534     123   0.93 (0.80 to 1.10)   0.414                 −3.3 (−14.2 to 3.9)   0.386                 
  Fully adjusted†   519     117   0.95 (0.80 to 1.13)   0.557                 −3.8 (−15.3 to 4.2)   0.541                 
  TRL-TG            Crude   495   112                   0.97 (0.82 to 1.15)   0.710                 −2.2 (−10.1 to 6.5)   0.617
  Age and sex       495     112   0.96 (0.81 to 1.15)   0.662                 −2.0 (−11.3 to 6.4)   0.588                 
  Fully adjusted†   480     106   0.98 (0.81 to 1.18)   0.828                 −1.4 (−11.6 to 7.1)   0.674                 
  RP                Crude   534   122                   1.06 (0.89 to 1.25)   0.532                 2.3 (−5.7 to 10.6)    0.558
  Age and sex       534     122   1.05 (0.89 to 1.25)   0.565                 1.1 (−4.5 to 9.2)     0.552                 
  Fully adjusted†   519     116   1.07 (0.90 to 1.28)   0.437                 1.3 (−5.2 to 9.4)     0.517                 
  apoBR             Crude   485   112                   0.91 (0.76 to 1.10)   0.340                 −1.2 (−9.8 to 7.5)    0.679
  Age and sex       485     112   0.91 (0.76 to 1.10)   0.344                 −1.3 (−11.0 to 7.3)   0.698                 
  Fully adjusted‡   470     106   0.93 (0.77 to 1.13)   0.460                 −1.5 (−12.3 to 6.7)   0.706                 

\*Estimate of IRD per 1000 person-years.

†Adjusted for age, sex, race and fasting blood glucose, following stepwise selection.

‡Adjusted for age, sex, race, fasting blood glucose and current smoking status, following stepwise selection.

apoBR, apolipoprotein B100 ratio; IRD, incident rate difference; PPL, postprandial lipemia; RP, retinyl palmitate; TG, postprandial triglycerides; TRL-TG, TG-rich lipoprotein triglycerides.

In stratified analyses, the smallest effect size capable of being detected with sufficient power was an HR=1.6 (in the subgroup of white participants). Similar to as in the overall sample, no significant associations between the PPL measures and incident CVD events were observed by race, BMI category or atherosclerosis severity (all p\>0.4). Point estimates of the associations between our PPL measures and CVD from each of these subgroup models were centered around the null value in a similar fashion as in the overall sample. Given the relatively smaller sample size of each subgroup compared to the overall sample, as expected, estimates were also less precise in stratified analyses. For brevity, quantitative results from stratified analyses are not depicted.

Conclusions {#s4}
===========

Extended follow-up of a well-characterised biracial sample of men and women did not reveal evidence of a relationship between exaggerated PPL response and increased incidence of CVD events. Further, no associations between the extent of PPL and incident CVD were observed by obesity status or level of carotid atherosclerosis.

Given the lack of statistically significant associations between our comprehensive measures of PPL and CVD risk, together with the consistently null-sized estimates of these associations, the results of this study suggest that PPL does not influence the risk of atherothrombotic events in a discernible way. Our negative findings mimic those from case--control studies that used a similar lipid load and postchallenge PPL measures,[@R2] [@R22] but they are not consistent with the significant (albeit modest) associations reported in considerably more powered prospective investigations.[@R3] However, these large-scale prospective studies were limited to non-standardised measures of fasting or non-fasting triglycerides assessed at only one time point. Our investigation was able to assess lipemic response over time using diverse lipoprotein and apolipoprotein measurements from a standardised fat challenge.

Equally important to acknowledge is the low statistical power of this study. Notwithstanding this limitation, until now, this is the largest and most extensive population-based study to examine the longitudinal association between PPL and CVD using standardised postchallenge lipid moieties as measures of PPL. Our findings ultimately point to excessive PPL not being as strong an independent predictor of CVD risk as previously indicated. Nevertheless, on the population level, PPL may be an important overall risk determinant and therapeutic target which influences other CVD risk factors such as HDL-C. Better powered prospective studies with detailed, standardised measures of postprandial change are needed to clarify the role (if any) of excessive PPL in CVD pathophysiology.
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